Study: Tandem’s AID can lower A1c in certain Type 2 diabetes patients

SAN DIEGO – Tandem Diabetes Care’s Control-IQ+ automated insulin delivery system can lower HbA1c’s in adults with insulin-treated Type 2 diabetes, according to a new study published in the American Diabetes Association’s Diabetes Care. The study, "Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level," is a sub-analysis from the 2IQP randomized, controlled trial. Of the 319 participants in the 2IQP trial, 254 were included in this specific analysis. Researchers categorized participants, all of whom had Type 2 diabetes and were using a t:slim X2 insulin pump with Control-IQ+ AID technology, into a 'high C-peptide' group (N=195) and a 'low C-peptide' group (N=59) based on CMS criteria. Participants in the AID group experienced a mean HbA1c decrease of 0.8% from baseline, which was significantly greater than the control group. This improvement was the same between the high and low C-peptide groups, demonstrating that the benefit of AID is present regardless of C-peptide levels. CMS criteria currently require a low C-peptide level for insulin pump coverage, which excludes many people with Type 2 diabetes from obtaining an AID system, even if they had already been benefiting from the technology prior to moving to Medicare. "The 2IQP trial demonstrated that AID provides benefits to adults with insulin-treated Type 2 diabetes across a range of demographics and treatment regimens, comparable to the outcomes seen in type 1 diabetes," said Irl B. Hirsch, MD, from the University of Washington School of Medicine and lead author of the manuscript. "These new analyses show that AID is effective regardless of C-peptide levels, indicating that a low C-peptide threshold should not be required for therapy."